Q-omics provides the consensus-scored AHCYP3 profile across patient tissues and cancer cell-line models. AHCYP3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, AHCYP3 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, AHCYP3 RNA expression shows 8,709 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CHOL, KICH, and KIRP as cancer lineages where AHCYP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AHCYP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AHCYP3 survival associations across molecular data types. AHCYP3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AHCYP3 RNA expression–survival associations across cancer types. High AHCYP3 expression shows unfavorable associations in CHOL, THYM, KICH and LIHC, but favorable associations in HNSC and LGG. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for AHCYP3 RNA expression.
This table summarizes AHCYP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for AHCYP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AHCYP3 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, KIRP and BRCA. The KICH box plot shows higher AHCYP3 RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p = .002).
This table shows molecular features associated with AHCYP3 in patient tissues and cancer cell lines. In patient samples, AHCYP3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
